Impact of CMV and EBV on immune recovery after allogeneic hematopoietic cell transplantation in children

7Citations
Citations of this article
27Readers
Mendeley users who have this article in their library.

Abstract

Background/Aim: Immune recovery is a key factor in the management of patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT). This study analyzed the factors contributing to immune reconstitution after allo-HSCT. Patients and Methods: Overall, 65 children with malignant or non-malignant diseases were included in multivariate analyses. Results: The following factors contributed to a faster immune recovery: peripheral blood as a stem cell source and reactivation of CMV infection for CD3+ and CD4+ lymphocyte subpopulations; reactivation of CMV infection for CD8+ subset; donor EBV-IgG+ and no EBV reactivation for CD19 lymphocytes; recipient age below 10 years and peripheral blood as a stem cell source for NK cells. For CD2 and CD4/CD8 ratio no factor was significant in multivariate analysis. Conclusion: Patients receiving a graft from an EBV-IgG-positive donor and not having early EBV posttransplant viremia show faster recovery of the B-cells, while patients with early CMV-DNA-emia have a better reestablishment of T-cell subsets.

Cite

CITATION STYLE

APA

Pukownik, E., Kubicka, M., Kurylo-Rafinska, B., Debski, R., Galazka, P., Czyzewski, K., … Styczynski, J. (2018). Impact of CMV and EBV on immune recovery after allogeneic hematopoietic cell transplantation in children. Anticancer Research, 38(10), 6009–6013. https://doi.org/10.21873/anticanres.12950

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free